Global Gesagliflozin Market Strategic Research Report

Scope of the Report

The global Gesagliflozin market size is predicted to grow from US$ 29.35 million in 2025 to US$ 160 million in 2032; it is expected to grow at a CAGR of 12.7% from 2026 to 2032.

In 2025, global Garsorasib production reached approximately 5000 units.Garsorasib Tablets (generic name: Garsorasib Tablets, trade name: Anfangning) is an independently developed oral small-molecule targeted antineoplastic drug in China for the treatment of KRAS G12C-mutant advanced non-small cell lung cancer (NSCLC), belonging to irreversible KRAS G12C inhibitors. Its mechanism of action is to specifically bind and lock the inactive conformation of the mutant KRAS protein, block the abnormal activation of the downstream MAPK signaling pathway, thereby inhibiting tumor cell proliferation and inducing tumor cell apoptosis. This product is a 200 mg yellow oval film-coated tablet, approved for marketing in China in November 2024. It is mainly indicated for adult patients with locally advanced or metastatic KRAS G12C-mutant non-small cell lung cancer who have received at least one prior systemic therapy. It serves as an important domestic innovative targeted drug in the field of precision therapy for lung cancer in China.

Garsorasib, as the second KRAS G12C inhibitor approved in China, occupies an important position in the underserved niche market of KRAS G12C-mutant non-small cell lung cancer, relying on the strong commercialization capability of Chia Tai Tianqing. With its inclusion in medical insurance and the successive launch of multiple domestic similar drugs (Fuzolasib, Golorasib, Jilemei), the market has shifted from an early "blue ocean" to a fiercely competitive stage. Its core advantages lie in domestic innovation, definite efficacy and favorable safety. In addition, price reduction through medical insurance negotiations has rapidly improved patient accessibility. In the future, market competition will focus on price, medical insurance coverage, clinical efficacy, combination therapy, indication expansion (such as colorectal cancer) and commercial channels. Relying on its first-mover advantage, medical insurance coverage and strong channels, Garsorasib is expected to maintain a stable share among similar domestic products, while facing challenges including price wars, medical insurance cost control and intensified competition from rival drugs.

Key Questions Addressed in this Report

What is the 10-year outlook for the global Gesagliflozin market?

What factors are driving Gesagliflozin market growth, globally and by region?

Which technologies are poised for the fastest growth by market and region?

How do Gesagliflozin market opportunities vary by end market size?

How does Gesagliflozin break out by Type, by Application?

This report presents a comprehensive overview of the global Gesagliflozin market, covering market size and forecast, segmentation by product type and application, competitive landscape, leading players and regional and country-level outlook.

Segment by Type

• 100mg
• 200mg

Segment by Combination Therapy

• Garsorasib and Immune Checkpoint Inhibitors
• Garsorasib and FAK Inhibitors

Segment by Production Technology

• Innovator
• Generic

Segment by Sales Channels

• Hospital
• Retail
• Online

Segment by Application

• KRAS G12C-Mutant Tumors
• Non-Small Cell Lung Cancer (NSCLC)
• Colorectal Cancer
• Pancreatic Cancer
• Others

Who Can Use This Report?

This report is written for decision-makers who need a clear, data-backed view of the global Gesagliflozin market:

• Manufacturers, suppliers and solution providers benchmarking their position and planning product, capacity and go-to-market strategy
• Distributors, channel partners and end users in KRAS G12C-Mutant Tumors, Non-Small Cell Lung Cancer (NSCLC), Colorectal Cancer evaluating demand and sourcing options
• Investors, financial analysts and consultants assessing growth opportunities, competitive dynamics and M&A potential
• Government agencies, industry associations and research institutions tracking industry developments and policy impact